These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10609697)

  • 41. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability.
    Chui HC; Mack W; Jackson JE; Mungas D; Reed BR; Tinklenberg J; Chang FL; Skinner K; Tasaki C; Jagust WJ
    Arch Neurol; 2000 Feb; 57(2):191-6. PubMed ID: 10681076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of seven sets of criteria used for the diagnosis of vascular dementia.
    Verhey FR; Lodder J; Rozendaal N; Jolles J
    Neuroepidemiology; 1996; 15(3):166-72. PubMed ID: 8700309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study.
    van Straaten EC; Scheltens P; Knol DL; van Buchem MA; van Dijk EJ; Hofman PA; Karas G; Kjartansson O; de Leeuw FE; Prins ND; Schmidt R; Visser MC; Weinstein HC; Barkhof F
    Stroke; 2003 Aug; 34(8):1907-12. PubMed ID: 12855825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of dementia and dementing diseases in Japan: the Tajiri project.
    Meguro K; Ishii H; Yamaguchi S; Ishizaki J; Shimada M; Sato M; Hashimoto R; Shimada Y; Meguro M; Yamadori A; Sekita Y
    Arch Neurol; 2002 Jul; 59(7):1109-14. PubMed ID: 12117358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognitive outcome measures.
    Ferris SH
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S140-2. PubMed ID: 10609693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)].
    Kapl D; Rudolphi KA
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 1998 Sep; 26(5):317-21. PubMed ID: 9931990
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort.
    Pohjasvaara T; Erkinjuntti T; Vataja R; Kaste M
    Stroke; 1997 Apr; 28(4):785-92. PubMed ID: 9099197
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia.
    Lopez OL; Larumbe MR; Becker JT; Rezek D; Rosen J; Klunk W; DeKosky ST
    Neurology; 1994 Jul; 44(7):1240-5. PubMed ID: 8035923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN).
    Wetterling T; Kanitz RD; Borgis KJ
    Stroke; 1996 Jan; 27(1):30-6. PubMed ID: 8553399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroimaging criteria for vascular dementia.
    Pullicino P; Benedict RH; Capruso DX; Vella N; Withiam-Leitch S; Kwen PL
    Arch Neurol; 1996 Aug; 53(8):723-8. PubMed ID: 8759977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.
    Román GC; Tatemichi TK; Erkinjuntti T; Cummings JL; Masdeu JC; Garcia JH; Amaducci L; Orgogozo JM; Brun A; Hofman A
    Neurology; 1993 Feb; 43(2):250-60. PubMed ID: 8094895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities.
    Bachynsky J; McCracken P; Lier D; Alloul K; Jacobs P
    Alzheimer Dis Assoc Disord; 2000; 14(2):102-11. PubMed ID: 10850749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer's disease with cerebrovascular disease.
    Karamacoska D; Chan DKY; Leung I; Liu JX; Brodaty H; Fahey PP; Bensoussan A; Chang DH
    PLoS One; 2023; 18(3):e0265285. PubMed ID: 36920949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The profile of behavioral and psychological symptoms in vascular cognitive impairment with and without dementia.
    Gupta M; Dasgupta A; Khwaja GA; Chowdhury D; Patidar Y; Batra A
    Ann Indian Acad Neurol; 2013 Oct; 16(4):599-602. PubMed ID: 24339588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia.
    Mielke R; Kittner B; Ghaemi M; Kessler J; Szelies B; Herholz K; Heiss WD
    J Neurol Sci; 1996 Sep; 141(1-2):59-64. PubMed ID: 8880694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type.
    Rother M; Kittner B; Rudolphi K; Rössner M; Labs KH
    Ann N Y Acad Sci; 1996 Jan; 777():404-9. PubMed ID: 8624121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single stroke dementia: insights from 12 cases in Singapore.
    Auchus AP; Chen CP; Sodagar SN; Thong M; Sng EC
    J Neurol Sci; 2002 Nov; 203-204():85-9. PubMed ID: 12417363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validity of the clinical diagnostic criteria for vascular dementia: a critical review. Part II.
    Wiederkehr S; Simard M; Fortin C; van Reekum R
    J Neuropsychiatry Clin Neurosci; 2008; 20(2):162-77. PubMed ID: 18451187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia.
    Ringheim GE
    Ann N Y Acad Sci; 2000 Apr; 903():529-34. PubMed ID: 10818548
    [No Abstract]   [Full Text] [Related]  

  • 60. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain.
    Sweitzer S; De Leo J
    Handb Exp Pharmacol; 2011; (200):235-50. PubMed ID: 20859798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.